Polyrizon raises $4M as intranasal hydrogel biotech taps single investor

What's the deal? PolyrizonDealroom has a profile for this one. Try Dealroom → (NASDAQ: PLRZ), an Israel-based development-stage biotech, has raised roughly $4 million through a registered direct offering and a concurrent private placement. Both transactions were sold to a single institutional investor.

What does Polyrizon do? The Raanana-based company develops intranasal hydrogels. It remains at the development stage, without a commercial product.

The terms: The deal priced units at $12.00 each, combining Ordinary Shares, pre-funded warrants, and common warrants exercisable at $12.00 per share. Aegis Capital Corp. acted as exclusive placement agent, with the offering expected to close on or about September 4, 2026.

What's the money for? Polyrizon plans to use the net proceeds, together with existing cash, for general corporate purposes and working capital. After closing, it will have 2,806,233 Ordinary Shares outstanding, assuming all pre-funded warrants are exercised.

The signal: At $4 million, the raise sits in the bottom quartile of comparable rounds — a modest injection that keeps a small-cap biotech funded rather than a bet on scale. For early-stage NASDAQ-listed biotechs, single-investor placements remain a routine way to extend runway.

Read more: Business Insider

Image credit: Generated with Gemini